A new inhibitor for fructosamine 3-kinase (amadorase)TSAI, Henry J; CHOU, Shan-Yen; KAPPLER, Frank et al.Drug development research. 2006, Vol 67, Num 5, pp 448-455, issn 0272-4391, 8 p.Article

Design and implementation of an activity-based costing system in a pharmaceutical drug discovery environmentCOULIE, Bernard; DE DECKER, Nadine; MAES, Vic et al.Drug development research. 2006, Vol 67, Num 2, pp 107-118, issn 0272-4391, 12 p.Article

The novel depot of buprenorphine propionate has a long-acting effect on physical dependence on morphineLIU, Kuo-Sheng; LIN, Ching-Nan; SHIEH, Ja-Ping et al.Drug development research. 2006, Vol 67, Num 5, pp 462-469, issn 0272-4391, 8 p.Article

CJZ3, a lomerizine derivative, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cellsJI, Bian-Sheng; LING HE; LIU, Guo-Qing et al.Drug development research. 2006, Vol 67, Num 11, pp 862-869, issn 0272-4391, 8 p.Article

Endothelin receptors as drug targets in chronic cardiovascular diseases : The rationale for dual antagonismCLOZEL, Martine; FLORES, Susan.Drug development research. 2006, Vol 67, Num 11, pp 825-834, issn 0272-4391, 10 p.Article

Targeting the p53 tumor suppressor gene function in glioblastomas using small chemical moleculesMAGRINI, Roberta; BAKKER, Annette; GAVIRAGHI, Giovanni et al.Drug development research. 2006, Vol 67, Num 10, pp 790-800, issn 0272-4391, 11 p.Article

Magnetic nanoparticles for drug deliveryDOBSON, Jon.Drug development research. 2006, Vol 67, Num 1, pp 55-60, issn 0272-4391, 6 p.Article

Effectiveness and outcome research studies: current trendsAPOLONE, Giovanni; GROSSI, Enzo.Drug development research. 2006, Vol 67, Num 3, issn 0272-4391, 109 p.Serial Issue

An active role for patients in clinical research?O'CONNELL, Deirdre; MOSCONI, Paola.Drug development research. 2006, Vol 67, Num 3, pp 188-192, issn 0272-4391, 5 p.Article

Neuropathic pain : Symptoms, models, and mechanismsBEEES, Simon; SALTER, Michael W.Drug development research. 2006, Vol 67, Num 4, pp 289-301, issn 0272-4391, 13 p.Article

Hypertension, diabetes, insulin resistance, and postprandial hyperglycemiaBELL, David S. H.Drug development research. 2006, Vol 67, Num 7, pp 595-596, issn 0272-4391, 2 p.Conference Paper

The importance of postprandial glucose concentration : Lessons learned from diabetes and pregnancyJOVANOVIC, Lois.Drug development research. 2006, Vol 67, Num 7, pp 591-594, issn 0272-4391, 4 p.Conference Paper

Toward the discovery of small molecule PTP1B inhibitors for the treatment of metabolic diseasesNICHOLS, Andrew J; MASHAL, Robert D; BALKAN, Bork et al.Drug development research. 2006, Vol 67, Num 7, pp 559-566, issn 0272-4391, 8 p.Conference Paper

Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disordersWITKIN, Jeffrey M; EILER, William J. A.Drug development research. 2006, Vol 67, Num 9, pp 757-769, issn 0272-4391, 13 p.Article

Novel estrogen receptor ligands and their structure-activity relationship evaluated by scintillation proximity assay for high-throughput screeningLING HE; HUA XIANG; ZHANG, Lu-Yong et al.Drug development research. 2005, Vol 64, Num 4, pp 203-212, issn 0272-4391, 10 p.Article

In vitro permeation of diclofenac sodium from novel microemulsion formulations through rabbit skinKANTARCI, Gülten; ÖZGÜNEY, Isik; KARASULU, Hatice Y et al.Drug development research. 2005, Vol 65, Num 1, pp 17-25, issn 0272-4391, 9 p.Article

Oncolytic viral therapy for human cancer : Challenges revisitedTONG, Alex W.Drug development research. 2005, Vol 66, Num 4, pp 260-277, issn 0272-4391, 18 p.Article

Monoamine reuptake inhibitors : Highlights of recent research developmentsWALTER, Magnus W.Drug development research. 2005, Vol 65, Num 3, pp 97-118, issn 0272-4391, 22 p.Article

Galanin receptors as novel drug targets for the treatment of depression and anxietyXIAOYING LU; BARR, Alasdair M; BARTFAI, Tamas et al.Drug development research. 2005, Vol 65, Num 4, pp 227-236, issn 0272-4391, 10 p.Article

Potential use of neurosteroids and neuroactive steroids as modulators of symptoms of depression, anxiety, and psychotic disordersDUBROVSKY, Bernardo.Drug development research. 2005, Vol 65, Num 4, pp 318-334, issn 0272-4391, 17 p.Article

Estrogens and NeuroprotectionHOWELL, Neil; DYKENS, James; MOOS, Walter H et al.Drug development research. 2005, Vol 66, Num 2, issn 0272-4391, 141 p.Serial Issue

Alzheimer's disease, estrogens, and clinical trials : A case study in drug development for complex disordersHOWELL, Neil; DYKENS, James; MOOS, Walter H et al.Drug development research. 2005, Vol 66, Num 2, pp 53-77, issn 0272-4391, 25 p.Article

Mapping the locations of estradiol and potent neuroprotective analogues in phospholipid bilayers by REDORCEGELSKI, Lynette; RICE, Charles V; O'CONNOR, Robert D et al.Drug development research. 2005, Vol 66, Num 2, pp 93-102, issn 0272-4391, 10 p.Article

A major role for astrocytes in the neuroprotective effect of estrogenSORTINO, Maria Angela; PLATANIA, Paola; CHISARI, Mariangela et al.Drug development research. 2005, Vol 66, Num 2, pp 126-135, issn 0272-4391, 10 p.Article

Lack of protective effect of estrogens on cerebral Aβ levels in intact female and male APP transgenic miceCHAKRABARTI, Enakshi; WANG, Jennifer; CLAIRE-OLSEN, Julia et al.Drug development research. 2005, Vol 66, Num 2, pp 136-141, issn 0272-4391, 6 p.Article